A research team compared mRNA vaccine technologies, which are used to make Spikevax and Comirnaty, with self-amplifying RNA systems like those being studied by Imperial College London and platforms that use adeno-associated virus (AAV) vectors. In terms of overall manufacturing cost, the RNA-based platforms won out, says Zoltan Kis, PhD, from the department of chemical and biological engineering at the University of Sheffield.